Literature DB >> 11256945

Alpha-melanocyte-related tripeptide, Lys-d-Pro-Val, ameliorates endotoxin-induced nuclear factor kappaB translocation and activation: evidence for involvement of an interleukin-1beta193-195 receptor antagonism in the alveolar epithelium.

J J Haddad1, R Lauterbach, N E Saadé, B Safieh-Garabedian, S C Land.   

Abstract

The potential anti-inflammatory role of alpha-melanocyte-stimulating hormone (alpha-MSH)-related tripeptide, lysine(11)-D-proline-valine(13) (KDPV), an analogue of interleukin (IL)-1beta(193-195) and an antagonist of IL-1beta/prostaglandin E(2), is not well characterized in the alveolar epithelium. In a model of foetal alveolar type II epithelial cells in vitro, we showed that lipopolysaccharide endotoxin (LPS) differentially, but selectively, induced the nuclear subunit composition of nuclear factor kappaB(1) (NF-kappaB(1)) (p50), RelA (p65) and c-Rel (p75), in parallel to up-regulating the DNA-binding activity (supershift indicating the presence of the p50-p65 complex). LPS accelerated the degradation of inhibitory kappaB-alpha (IkappaB-alpha), accompanied by enhancing its phosphorylation in the cytosolic compartment but not in the nucleus. KDPV suppressed, in a dose-dependent manner, the nuclear localization of p50, p65 and p75, an effect that led to the subsequent inhibition of NF-kappaB activation. Interleukin-1 receptor antagonist (IL-1ra) decreased the nuclear abundance of p50, p65 and p75, and subsequently depressed the DNA-binding activity induced by LPS. Analysis of the mechanism involved in the KDPV- and IL-1ra-mediated inhibition of NF-kappaB nuclear localization revealed a reversal in IkappaB-alpha phosphorylation and degradation, followed by cytosolic accumulation. LPS induced endogenous IL-1beta biosynthesis in a time-dependent manner; the administration of exogenous recombinant human interleukin 1 (rhIL-1) resulted in a dose-dependent activation of NF-kappaB. KDPV and IL-1ra abrogated the effect of rhIL-1. Pretreatment with the non-steroidal anti-inflammatory drug (NSAID) indomethacin, an inhibitor of cyclo-oxygenase, blocked the LPS-induced activation of NF-kappaB. These results indicate the involvement of prostanoid-dependent (NSAID-sensitive) and IL-1-dependent (IL-1ra-sensitive) mechanisms mediating LPS-induced NF-kappaB translocation and activation, a pathway that is regulated, in part, by a negative feedback mechanism transduced through IkappaB-alpha, the major cytosolic inhibitor of NF-kappaB.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11256945      PMCID: PMC1221708          DOI: 10.1042/0264-6021:3550029

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  33 in total

1.  IkappaB kinase-beta: NF-kappaB activation and complex formation with IkappaB kinase-alpha and NIK.

Authors:  J D Woronicz; X Gao; Z Cao; M Rothe; D V Goeddel
Journal:  Science       Date:  1997-10-31       Impact factor: 47.728

2.  Expression of oxidative stress-responsive genes and cytokine genes during caerulein-induced acute pancreatitis.

Authors:  K Fu; M P Sarras; R C De Lisle; G K Andrews
Journal:  Am J Physiol       Date:  1997-09

3.  A cytokine-responsive IkappaB kinase that activates the transcription factor NF-kappaB.

Authors:  J A DiDonato; M Hayakawa; D M Rothwarf; E Zandi; M Karin
Journal:  Nature       Date:  1997-08-07       Impact factor: 49.962

4.  Alpha-melanocyte-stimulating hormone reduces endotoxin-induced liver inflammation.

Authors:  H Chiao; S Foster; R Thomas; J Lipton; R A Star
Journal:  J Clin Invest       Date:  1996-05-01       Impact factor: 14.808

5.  alpha-melanocyte-stimulating hormone inhibits NF-kappaB activation and IkappaBalpha degradation in human glioma cells and in experimental brain inflammation.

Authors:  T Ichiyama; H Zhao; A Catania; S Furukawa; J M Lipton
Journal:  Exp Neurol       Date:  1999-06       Impact factor: 5.330

6.  alpha-MSH and its receptors in regulation of tumor necrosis factor-alpha production by human monocyte/macrophages.

Authors:  S Taherzadeh; S Sharma; V Chhajlani; I Gantz; N Rajora; M T Demitri; L Kelly; H Zhao; T Ichiyama; A Catania; J M Lipton
Journal:  Am J Physiol       Date:  1999-05

7.  Systemically administered alpha-melanocyte-stimulating peptides inhibit NF-kappaB activation in experimental brain inflammation.

Authors:  T Ichiyama; T Sakai; A Catania; G S Barsh; S Furukawa; J M Lipton
Journal:  Brain Res       Date:  1999-07-31       Impact factor: 3.252

8.  Systemic alpha-MSH suppresses LPS fever via central melanocortin receptors independently of its suppression of corticosterone and IL-6 release.

Authors:  Q H Huang; V J Hruby; J B Tatro
Journal:  Am J Physiol       Date:  1998-08

9.  Alpha-melanocyte-stimulating hormone inhibits the nuclear transcription factor NF-kappa B activation induced by various inflammatory agents.

Authors:  S K Manna; B B Aggarwal
Journal:  J Immunol       Date:  1998-09-15       Impact factor: 5.422

10.  Alpha-MSH peptides inhibit production of nitric oxide and tumor necrosis factor-alpha by microglial cells activated with beta-amyloid and interferon gamma.

Authors:  D Galimberti; P Baron; L Meda; E Prat; E Scarpini; R Delgado; A Catania; J M Lipton; G Scarlato
Journal:  Biochem Biophys Res Commun       Date:  1999-09-16       Impact factor: 3.575

View more
  9 in total

1.  The biphasic immunoregulation of pyrimidylpiperazine (Y-40138) is IL-10 sensitive and requires NF-kappa B targeting in the alveolar epithelium.

Authors:  J J Haddad; B Safieh-Garabedian; N E Saadé; S C Land
Journal:  Br J Pharmacol       Date:  2001-05       Impact factor: 8.739

2.  Redox/ROS regulation of lipopolysaccharide-induced mitogen-activated protein kinase (MAPK) activation and MAPK-mediated TNF-alpha biosynthesis.

Authors:  J J Haddad; S C Land
Journal:  Br J Pharmacol       Date:  2002-01       Impact factor: 8.739

3.  Histone Lys demethylase KDM3C demonstrates anti-inflammatory effects by suppressing NF-κB signaling and osteoclastogenesis.

Authors:  Jae Young Lee; Shebli Mehrazarin; Abdullah Alshaikh; Sol Kim; Wei Chen; Renate Lux; Yousang Gwack; Reuben H Kim; Mo K Kang
Journal:  FASEB J       Date:  2019-06-28       Impact factor: 5.191

Review 4.  Chiral secondary amino acids, their importance, and methods of analysis.

Authors:  Helena Zahradníčková; Stanislav Opekar; Lucie Řimnáčová; Petr Šimek; Martin Moos
Journal:  Amino Acids       Date:  2022-02-21       Impact factor: 3.520

5.  PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation.

Authors:  Guillaume Dalmasso; Laetitia Charrier-Hisamuddin; Hang Thi Thu Nguyen; Yutao Yan; Shanthi Sitaraman; Didier Merlin
Journal:  Gastroenterology       Date:  2007-10-17       Impact factor: 22.682

6.  Structural modification of the tripeptide KPV by reductive "glycoalkylation" of the lysine residue.

Authors:  Abigael C Songok; Pradip Panta; William T Doerrler; Megan A Macnaughtan; Carol M Taylor
Journal:  PLoS One       Date:  2018-06-28       Impact factor: 3.240

Review 7.  Science review: Redox and oxygen-sensitive transcription factors in the regulation of oxidant-mediated lung injury: role for nuclear factor-kappaB.

Authors:  John J Haddad
Journal:  Crit Care       Date:  2002-10-14       Impact factor: 9.097

Review 8.  Oxygen-sensing mechanisms and the regulation of redox-responsive transcription factors in development and pathophysiology.

Authors:  John J Haddad
Journal:  Respir Res       Date:  2002-11-22

9.  Single administration of tripeptide α-MSH(11-13) attenuates brain damage by reduced inflammation and apoptosis after experimental traumatic brain injury in mice.

Authors:  Eva-Verena Schaible; Arne Steinsträßer; Antje Jahn-Eimermacher; Clara Luh; Anne Sebastiani; Frida Kornes; Dana Pieter; Michael K Schäfer; Kristin Engelhard; Serge C Thal
Journal:  PLoS One       Date:  2013-08-05       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.